Nabriva Therapeutics plc (NBRV) and its China-based partner Sinovant Sciences have reported positive topline results from a phase III bridging study of Lefamulin in Chinese adults with community acquired bacterial pneumonia.
from RTT - Top Story https://ift.tt/34jrJ6q
via IFTTT
from RTT - Top Story https://ift.tt/34jrJ6q
via IFTTT
Comments
Post a Comment